Pegylated Somatropin in the Treatment of Children With Growth Hormone Deficient A Multicenter, Randomized, Open-label, Controlled Phase Ⅲ Clinical Trial

Trial Profile

Pegylated Somatropin in the Treatment of Children With Growth Hormone Deficient A Multicenter, Randomized, Open-label, Controlled Phase Ⅲ Clinical Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Sponsors GeneScience Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top